Result: 74 patients were recruited with the following characteristics: mean age 68.4 ± 15.1; 93.2% were male; 91.9% had co-morbidities; 85.1% had PS1; tumor position in the oral cavity 17.6%, oropharynx 32.4%, hypopharynx 17.6%, larynx 24.3%, nasal cavity 8.1%; stage IV 70.2%; BED radiation dose was mainly 70Gy (86.5%); 3D (46.0%), IMRT (54.0%); compliance rate with cetuximab 91.9%; toxicity grade 3 or more including dermatitis 37.8%, mucositis 58.1%, skin rash 12.1%.